Ticker LaunchReverse merger · Completed · KRRO
Korro Bio, Inc.
Reverse merger with Frequency Therapeutics, Inc.
Korro Bio, Inc. merged into Frequency Therapeutics, Inc., a Nasdaq-listed biotech that ended its multiple sclerosis programs, assets covered by CVR, in a reverse merger that takes the private company public. The deal was announced on Jul 14, 2023 and closed on Nov 3, 2023. The combined company trades as Korro Bio, Inc. (KRRO) on Nasdaq.
Korro Bio is a biopharmaceutical company advancing a wholly owned portfolio of RNA editing programs. Its lead product candidate for alpha-1 antitrypsin deficiency is headed into a clinical trial, with post-transaction cash of about $170 million funding operations into 2026.
- Status
- Completed
- Private company
- Korro Bio, Inc.
- Public company
- Frequency Therapeutics, Inc.
- Public company business before
- Nasdaq-listed biotech that ended its multiple sclerosis programs, assets covered by CVR
- Announced
- Jul 14, 2023
- Closed
- Nov 3, 2023
- Combined company
- Korro Bio, Inc. (KRRO)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Contingent value rights (CVR)
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Nov 6, 2023
- Closing press release
- Merger agreement 8-K Jul 14, 2023
- All filings on EDGAR CIK 1703647
Other completed reverse mergers
- Neurogene Inc.into Neoleukin Therapeutics, Inc. · Dec 19, 2023
- Two Trees Beverage Companyinto MDwerks, Inc. · Dec 8, 2023
- Cartesian Therapeutics, Inc.into Selecta Biosciences, Inc. · Nov 13, 2023
- Beijing Continent Pharmaceuticals Co., Ltd. (via GNI Group)into Catalyst Biosciences, Inc. · Oct 30, 2023
- Tourmaline Bio, Inc.into Talaris Therapeutics, Inc. · Oct 19, 2023
- Notable Labs, Inc.into Vascular Biogenics Ltd. · Oct 16, 2023